Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €6.01 EUR
Change Today -0.02 / -0.33%
Volume 11.4K
As of 11:35 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

stentys (STNT) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/5/14 - €10.20
52 Week Low
10/16/14 - €3.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STENTYS (STNT)

Related News

No related news articles were found.

stentys (STNT) Related Businessweek News

No Related Businessweek News Found

stentys (STNT) Details

STENTYS Société anonyme, a medical technology company, engages in the development and commercialization of self-apposing stents to treat acute myocardial infarction, bifurcation lesions, and other complex coronary diseases in European countries. The company’s Self-Apposing stent technology consists of a self-expanding stent platform to treat coronary arteries with ambiguous vessel diameters or with areas of vessel diameter fluctuations. Its products portfolio includes the Self-Apposing STENTYS bare metal stents and DES (P) stents; and the STENTYS AC aspiration catheter, a deliverable thrombectomy device for thrombus-containing lesions. The company serves interventional cardiologists in Europe, the Middle East, and Asia. STENTYS Société anonyme was founded in 2006 and is headquartered in Paris, France.

39 Employees
Last Reported Date: 04/14/15
Founded in 2006

stentys (STNT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: €213.8K
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

stentys (STNT) Key Developments

Stentys Announces the Finding of First Xposition® Clinical Experience

STENTYS announced that the findings of the first Xposition® clinical experience, as part of the SETUP trial, were presented at the EuroPCR conference. Xposition S is STENTYS™ next-generation sirolimus-eluting Self-Apposing stent. It is delivered by a unique stent delivery system that closely replicates conventional stent implantation techniques: a small balloon peels the sheath containing the stent to release it precisely at the intended location. The SETUP study was a prospective, single-arm first-in-man study performed in two Dutch centers (Academic Medical Center, Amsterdam, and Albert Schweitzer Hospital, Dordrecht) to evaluate the feasibility of the use of the novel STENTYS Xposition S in de novo coronary lesions. The study enrolled 25 patients and demonstrated 100% technical and angiographic success rates without longitudinal geographical miss on quantitative coronary angiography (QCA). Stent strut malapposition as assessed by optical coherence tomography (OCT) was very low (0.6%) at the end of the procedure.

STENTYS Announces Unaudited Revenue Results for the First Quarter of 2015

STENTYS announced unaudited revenue results for the first quarter of 2015. For the quarter, the company reported revenues of EUR 1,093,800 against EUR 853,900 a year ago.

STENTYS Reports Consolidated Earnings Results for the Year Ended December 31, 2014

STENTYS reported consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenues €3.851 million compared to €3.394 million a year ago. These results were essentially achieved with the former self-apposing stents (PES and BMS), as the renewed portfolio was not marketed until the end of the year. Current operating loss (before share-based payment and non-current expense) was €13.111 million against €11.79 million a year ago. Operating loss was €18.116 million against €11.983 million a year ago. Net loss was €17.834 million against €11.729 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STNT:FP €6.01 EUR -0.02

STNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.03 USD -0.31
Boston Scientific Corp $17.83 USD -0.04
InspireMD Inc $0.24 USD +0.03
Medtronic PLC $77.82 USD -0.59
Sorin SpA €2.63 EUR -0.028
View Industry Companies

Industry Analysis


Industry Average

Valuation STNT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.1x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STENTYS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at